Irritable Bowel Syndrome With Constipation (IBS-C)

DBCOND0064306Digestive System Diseases Infections

Irritable Bowel Syndrome With Constipation (IBS-C) is the indication for 5 drugs in DrugBank. It is covered by 7 curated, structured indications.

Also known as: Irritable Bowel Syndrome (IBS-C) · Irritable Bowel Syndrome With Constipation · Irritable Bowel Syndrome-Constipation · IBS, Constipation Predominant · Constipation-Predominant Irritable Bowel Syndrome
Classified under: Digestive System Diseases
Infections
Mental Disorders
Indicated drugs: Linaclotide
Lubiprostone
Plecanatide
Tegaserod
Tenapanor

Resolves to

Vocabularies

MeSHM0004816ICD-10K58SNOMED CT10743008MedDRA10009897UMLSC0022104

What you can answer from here — as of October 22, 2026

5Indicated drugsWith each drug's targets and mechanism

Listed above

7Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

54Clinical trialsPhase, status and sponsor resolved per trial

3Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Irritable Bowel Syndrome With Constipation (IBS-C) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account